Dong Kim
Chief Executive Officer AevisBio Inc.
Dong Seok Kim is the founder of Aevis Bio, with extensice experience in both basic and transltaional research in relation to the ubiquitin-proteasome system in cancer biology and immunology. At Aevis Bio, his work focuses on the development of the Molecular Glue Degrader discovery platform to identify novel scaffolds applicable to multipel drug targets.
Seminars
Monday 27th October 2025
Accelerating Molecular Glue Discovery with CBM/PDL Platforms for Novel Target Engagement
9:00 am
- Leveraging a structurally distinct cereblon-binding module (CBM) library to recruit novel neosubstrates beyond traditional thalidomide analogues
- Deploying a proteomics-based degron library (PDL) to predict degron motifs and prioritize new molecular glue degrader (MGD) targets
- Highlighting case studies of MGD discovery and optimization to expand druggable target space
